Pfizer Ltd. — Regulatory Filings 2021

Jun 1, 2021

Pfizer Limited

==> picture [94 x 39] intentionally omitted <==

The Capital, 1802/1901, Plot No. C - 70, G Block, Bandra Kurla Complex, Bandra (East), Mumbai 400 051. Tel : +91 22 6693 2000 Fax : +91 22 2654 0274

June 1, 2021

The Corporate Relationship Dept. BSE Limited[st] Floor, P.J.Towers Dalal Street, Fort Mumbai - 400 001 Scrip Code: 500680

The Manager, Listing Dept. The National Stock Exchange of India Ltd. Exchange Plaza, 5[th] Floor, Plot No. C/1, G Block Bandra-Kurla Complex, Bandra (E) Mumbai - 400 051 Scrip Symbol: PFIZER

Dear Sirs,

Sub: Disclosure under Regulation 23(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘Listing Regulations’)

Pursuant to Regulation 23(9) of the Listing Regulations, please find enclosed, disclosure of related party transactions on a consolidated basis, in the format specified in the accounting standards for the year ended March 31, 2021.

The said disclosure is also available on the website of the Company i.e., www.pfizerindia.com

Please take the above on record.

Thanking you,

Yours truly,

For Pfizer Limited

==> picture [105 x 52] intentionally omitted <==

Prajeet Nair Company Secretary

CIN: L24231MH1950PLC008311 Email ID: contactus.india@pfizer.com Website: www.pfizerindia.com

Pfizer Limited

DISCLOSURE OF RELATED PARTY TRANSACTIONS FOR THE FINANCIAL YEAR ENDED MARCH 31, 2021

Currency: ₹ in crore

Related party transactions

I. Names of related parties and description of relationships

A. Parties where control exists:

Ultimate holding company: Pfizer Inc., USA B. Companies collectively exercising significant influence: Pfizer East India B.V., Netherlands Wyeth LLC, USA Wyeth Holdings Corporation, USA John Wyeth & Brother Limited, UK Warner - Lambert Company, LLC, USA Parke - Davis & Company, LLC, USA Pharmacia Corporation, USA [Collectively holding 63.92% of the aggregate of equity share capital of the Company]

C. Fellow subsidiaries with whom transactions have taken place during the year Pfizer Products India Private Limited, India Pfizer Innovative Supply Point International BVBA, Belgium ( upto 30 November 2020) Pfizer Service Company BVBA, Belgium Pfizer Worldwide Services, Ireland Pfizer Asia Manufacturing PTE, Singapore Pfizer Healthcare India Private Limited D. Key managerial personnel

Mr. S. Sridhar - Managing Director

Mr. Milind Patil - Wholetime Director & Chief Financial Officer

Mr. Vivek Dhariwal - Wholetime Director (upto 14 February 2020) Mr. Samir Kazi - Wholetime Director Mr. R A Shah - Independent Director Mr. Pradip Shah - Independent Director Mr. Uday Khanna - Independent Director Mr. Sunil Lalbhai - Independent Director Ms.Meena Ganesh - Independent Director E. Relative of Key managerial personnel Mr. Akhilesh Iyer F. Companies in which directors are key managerial personnel/member Crawford Bayley & Co Healthvista India Private Limited Medybiz Pharma Private Limited

Pfizer Limited

DISCLOSURE OF RELATED PARTY TRANSACTIONS FOR THE FINANCIAL YEAR ENDED MARCH 31, 2021

Currency: ₹ in crore

Related party transactions (Continued)

II. Transactions during the year and balances outstanding as at the year end with the related parties are as follows:

		31 March 2021	31 March 2021	31 March 2021	31 March 2021	31 March 2020	31 March 2020
	No. Nature of transactions Ultimate holding company Companies exercising significant influence Fellow subsidiaries Companies in which directors are exercising significant influence Total					Ultimate holding company Companies exercising significant influence Fellow subsidiaries Companies in which directors are exercising significant influence Total
	1 Service income - - 48.39 - 48.39 2 Recovery of expenses 11.64 - 0.48 - 12.12 3 Purchase of stock-in-trade - - 367.48 - 367.48 4 Purchase of raw / bulk materials - - 44.19 - 44.19 5 Dividend in respect of the year ended 31 March 2020/ 2019 - 965.02 - - 965.02 6 Liablity written back - - - - - 7 Asset transfer 2.12 - - 2.12 8 Liablity transfer - - 0.16 - 0.16 9 Compensation for wind down of consumer business 27.50 - - - 27.50 10 Service fee - - - 0.87 0.87					- - 55.19 - 55.19 0.54 0.03 0.19 - 0.76 - - 393.41 - 393.41 - - 115.05 - 115.05 - 65.77 - - 65.77 - 1.42 8.59 - 10.01 - - - - - - - - - - - - - - - -- 0.45 0.45
	31 March 2021					31 March 2020
	No. Nature of transactions Ultimate holding company Companies exercising significant influence Fellow subsidiaries Total				Ultimate holding company Companies exercising significant influence Fellow subsidiaries Total
	11 Outstanding as at the year end – Due from (Refer note 39.15 0.10 20.14 59.39 11 and 14) 12 Outstanding as at the year end – Due to( (Refer note 20) 2.09 3.87 135.84 141.80				0.54 0.09 20.9921.62 11.18 6.47 271.20 288.85
	Key managerial personnel No. Nature of transactions Year ended 31 March 2021 Year ended 31 March 2020
	No. Nature of transactions Year ended 31 March 2021		Year ended 31 March 2020
	1 Remuneration to keymanagementpersonnel 11.32* 9.22

• Excludes amounts payable to key management personnel towards gratuity and compensated absences.

Details of material transactions during the year:

	Details of material transactions during the year:
	Year ended 31 March 2021 Year ended 31 March 2020
	a) Service income
	Pfizer Products India Private Limited 22.84 25.60 Pfizer Worldwide Services 25.55 29.59
	b) Recovery of expenses
	Pfizer Products India Private Limited 0.48 0.19
	Pfizer Inc., USA 11.64 0.54 c) Purchase of stock in trade
	Pfizer Innovative Supply Point Intl BVBA, Belgium 23.18 66.07 Pfizer Service Company BVBA, Belgium 344.30 327.34 d) Purchase of raw/ bulk materials Pfizer Service Company BVBA, Belgium 38.97 111.62
	e) Dividend paid
	Pfizer East India B.V. 600.15 40.92 Wyeth LLC, USA 185.38 12.64
	f) Remuneration to key management personnel
	S. Sridhar 5.03 4.11 Milind Patil 2.73 2.10 Vivek Dhariwal - 1.88 Samir Kazi 1.90 0.16

Pfizer Limited

DISCLOSURE OF RELATED PARTY TRANSACTIONS FOR THE FINANCIAL YEAR ENDED MARCH 31, 2021

Currency: ₹ in crore

Related party transactions (Continued)

	Related party transactions(Continued)
		As on 31 March 2021	As on 31 March 2020
	g) Outstanding as at the year end due from Pfizer Worldwide Services Pfizer Products India Private Limited, India Pfizer Inc h) Outstanding as at the year end due to	1.20 18.94 39.15	5.70 15.29 -
	Pfizer Innovative Supply Point Intl BVBA, Belgium	8.12	15.81
	Pfizer Service Company BVBA, Belgium Pfizer Export Company, Ireland	23.79 82.38	152.55 82.85